The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Gaviscon Extra Oral Suspension Sodium alginate 500 mg Sodium bicarbonate 213 mg Calcium carbonate 325 mg

500 mg+213 mg+325 milligram(s) Oral suspension

Reckitt Benckiser Ireland LtdPA0979/015/011

Main Information

Trade NameGaviscon Extra Oral Suspension Sodium alginate 500 mg Sodium bicarbonate 213 mg Calcium carbonate 325 mg
Active SubstancesSodium alginate
Sodium bicarbonate
Calcium carbonate
Strength500 mg+213 mg+325 milligram(s)
Dosage FormOral suspension
Licence HolderReckitt Benckiser Ireland Ltd
Licence NumberPA0979/015/011

Group Information

ATC CodeA02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
A02BX13 alginic acid

Status

Authorised/WithdrawnAuthorised
Licence Issued01/10/2010
Legal statusProduct not subject to medical prescription
Supply StatusSupply through non-pharmacy outlets and pharmacies
Advertising StatusAdvertising to the general public
Conditions of LicenceGeneral Sale: Maximum pack size 600ml
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back